About
Pipeline
- Canine Pipeline
- Clinical Trials
Products
- Zimeta^™ (dipyrone injection)
Technology
- Veterinary Recombinant Biologics
- Manufacturing Process
Education
- Continuing Education
- KINections
Investors
News
- Press Releases
Contact Us
- Contact Us
- Careers
Menu

Test PI PDF Embed

You are here: Home / Test PI PDF Embed

Mirataz_Full_PI

News

Elanco Announces Agreement to Acquire Kindred BiosciencesJune 16, 2021 - 6:57 am
Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by ParvovirusJune 2, 2021 - 8:45 am
Kindred Biosciences to Present at Stifel 2021 Virtual Jaws & Paws Conference and LD Micro Invitational XIMay 25, 2021 - 8:57 am

Events

Event: Kindred Biosciences to Present at the LD Micro Invitational XIMay 25, 2021 - 9:14 am
Event: Kindred Biosciences to Present at the Stifel 2021 Virtual Jaws & Paws ConferenceMay 25, 2021 - 9:12 am
Event: Kindred Biosciences to Announce Fourth Quarter and Full Year 2020 Financial ResultsMarch 8, 2021 - 8:48 am

$9.20

0.01 (0.05%)

KIN (Common Stock)
Previous Close	Volume
$9.19	881,437
Intraday High	Intraday Low
$9.27	$9.19
52 Week High	52 Week Low
$9.28	$3.20
Exchange: NASDAQ CM

Contact Us | Careers | Privacy Policy | Website Terms of Use | Forward Looking Statements

© Copyright 2012-2020 | Kindred Biosciences, Inc. | 1555 Bayshore Hwy. Suite 200 Burlingame, CA 94010